OS Therapies Inc
OST-HER2
osteosarcoma
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for OST-HER2 in osteosarcoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company’s recently submitted clinical efficacy data includes 2-year overall survival data, with EMA requesting updated 2.5-year overall survival data that will be available by the middle of the second quarter of 2026, and 3-year overall”